📚 Part of the GLP-1 Receptor Agonists Trial Guide — every landmark trial in one place. Clinical Context GLP-1 receptor…
Browsing: Cardiovascular
Cardiovascular outcomes, heart failure, cardio-renal protection, hypertension, and lipid-lowering trials in diabetes and endocrinology.
Summary: In patients undergoing laparoscopic sleeve gastrectomy (LSG), a combination of preoperative HDL-C and visceral adipose tissue (VAT) significantly predicted…
Clinical Context Curcumin, the principal bioactive compound in turmeric (Curcuma longa), has been studied extensively for anti-inflammatory, antioxidant, and metabolic…
A prespecified DARE-19 analysis found dapagliflozin was safe and well tolerated in hospitalised COVID-19 patients regardless of type 2 diabetes status, with no demonstrated efficacy benefit. PICO summary and expert commentary.
A DAPA-MI subanalysis finds dapagliflozin reduces new-onset diabetes after heart attack regardless of glucose or BMI, with most symptom benefit in prediabetes. PICO summary and commentary.
Summary: In patients with clinically significant macular edema (CSME) in type 2 diabetes mellitus, low-dose atorvastatin (10-20 mg) significantly improved…
A post-hoc analysis of 307 ACCORD-BP participants with type 2 diabetes and prior stroke links intensive systolic blood pressure control to fewer cardiovascular events. PICO summary and expert commentary.
A 52-week trial finds semaglutide shifts lipoprotein subfractions toward a less atherogenic profile in type 2 diabetes, independent of weight or glucose change. PICO summary and commentary.
An ACCORD analysis finds a triglyceride-glucose-waist index independently predicts cardiovascular events and mortality in type 2 diabetes, beating TyG alone. PICO summary and commentary.
A randomised trial finds dapagliflozin reduces myocardial fibrosis and improves cardiac structure in diabetic HFpEF. PICO summary and expert commentary.